For chronic pain sufferers, there is a real problem with the abuse of painkillers in the United States. While the number of patients who have a legitimate need for prescription painkillers — 100 million plus — is vastly more than the number of people addicted to painkillers — 11 million — there is a stigma attached to the prescribing, dispensing and utilization of pain medicines.
As part of the launch of DSN’s new microsite, DrugStoreNews.com/Pain-Management, DSN had the opportunity to speak with Carmen Catizone, executive director of the National Association of Boards of Pharmacy, regarding a new initiative that the association is spearheading to address the current patient access problem when it comes to pain management pharmaceuticals.
News stories about doctor shopping and prescription pad pilfering in pursuit of a pain-pill induced high have become commonplace, prompting many legislators and regulators to consider further restrictions on pain medicines like hydrocodone compounds. But there may be a story that’s not being told — that the patients who suffer from chronic pain and need that hydrocodone to reclaim their lives are being stigmatized. The prevalence of pain pill abuse has left in its wake as many as 116 million legitimate pain sufferers who are finding it more difficult to access their therapies.
One reason pain patient advocates are so passionate about what they do is because they are pain patients themselves — they know the stigma associated with chronic pain; they know how difficult it can be to access appropriate pain therapy sometimes. That’s the story of Gina Libby, volunteer pain patient advocate who has lived with chronic pain for more than 20 years.
Health care providers wrote 259 million prescriptions for opioid painkillers in 2012 — many more in some states than in others — according to a Vital Signs report released Tuesday by the Centers for Disease Control and Prevention that highlights the danger of overdose.
The House Energy and Commerce Committee on Tuesday advanced bipartisan legislation sponsored by full committee vice chair Marsha Blackburn to address the nation’s growing prescription drug abuse epidemic.
As many as 40% of U.S. narcotic prescriptions in 2011-2012 were written by only 5% of opioid prescribers, according to a study Express Scripts presented Monday at AcademyHealth's annual research meeting.
As a key Congressional committee is set to consider legislation to help identify solutions for prescription drug abuse while preserving patients’ legitimate access to needed medications, the National Association of Chain Drug Stores has sent a letter to the bipartisan leadership of the House Energy and Commerce committees’ Health subcommittee affirming support for this effort, NACDS has announced.
Purdue Pharma on Wednesday announced that it filed a new drug application with the Food and Drug Administration to market a hydrocodone bitartrate tablet, which is formulated to incorporate abuse-deterrent technology.
The National Association of Chain Drug Stores submitted a written statement in lead-up to Monday’s hearing of the U.S. House Committee on Energy and Commerce Subcommittee on Health urging transparency in how federal agencies conduct enforcement activities to help curb prescription drug diversion and abuse.
The Drug Store News Group, the leading provider of news, information and clinical education for the retail pharmacy industry, has launched the new microsite, Drugstorenews.com/pain-management, to help bring attention to another tragic side of the prescription drug abuse story — the millions of Americans who live in chronic pain that may be unable to access the medications they need thanks to proposed changes in regulatory policy.
Purdue Pharma recently announced that a Phase 3 study of an investigational extended‐release formulation of hydrocodone bitartrate met its primary efficacy endpoint by showing that patients with chronic low back pain treated with the once‐daily analgesic agent experienced statistically significant reduction in pain compared with placebo.
Mallinckrodt Plc last week announced that the Food and Drug Administration approved Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), for the management of acute pain severe enough that it requires opioid treatment.